Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study
| ISRCTN | ISRCTN94465562 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN94465562 |
| Secondary identifying numbers | N0025107242 |
- Submission date
- 12/09/2003
- Registration date
- 12/09/2003
- Last edited
- 31/03/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr A Guha
Scientific
Scientific
Anaesthesia
University Hospital Aintree
Longmoor Lane
Fazakerley
Liverpool
L9 7AL
United Kingdom
| Phone | +44 (0)151 529 5152 / 5153 |
|---|---|
| abc@email.com |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study |
| Study objectives | Erythromycin's effect on gastric emptying in intensive care |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Signs and Symptoms: Gastric emptying |
| Intervention | A 5 ml sample of blood will be taken for measuring baseline paracetamol content. 1.5 g of soluble paracetamol will be administered to them through their nasogastric tube. They will then be randomised to receive 250 g of either nasogastric or intravenous erythromycin. Further blood samples (5 ml each time) will be taken at 15, 30, 45, 60, 120, 180 and 240 min after giving paracetamol. These samples will then be sent to the laboratory for assay. After obtaining the data, these will be analysed for statistical significance. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Erythromycin |
| Primary outcome measure | Not provided at time of registration |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 01/01/2002 |
| Completion date | 01/07/2003 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Not provided at time of registration |
| Key inclusion criteria | Intensive Care patients who will be recruited into the study if they exhibit a failure to absorb nasogastric feed. |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/2002 |
| Date of final enrolment | 01/07/2003 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University Hospital Aintree
Liverpool
L9 7AL
United Kingdom
L9 7AL
United Kingdom
Sponsor information
Department of Health (UK)
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Website | http://www.doh.gov.uk |
|---|
Funders
Funder type
Hospital/treatment centre
Aintree Hospitals NHS Trust (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
31/03/2020: No publications found, all search options exhausted, study status unverified.
